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It has been reported that microparticles generated from T lymphocytes undergoing
activation and apoptosis, bear the morphogen Sonic Hedgehog (MPsShh+), and
possessed the dual ability to increase NO and reduce ROS productions. Here, we
investigated whether MPsShh+ protected human umbical vein endothelial cells
(HUVECs) against actinomycin D (ActD)-induced apoptosis. MPsShh+ were obtained
by activation of human lymphocyte with phytohemagglutinin and then, by stimulation
with phorbol-12 myristate-13 acetate and ActD. HUVECs were grown for 24 h in
absence or presence of pro-apoptotic agent, ActD (1 μg/mL), and/or 10 μg protein/mL
of MPsShh+. Apoptosis evaluation was based on flow cytometry, TUNEL labelling
and cytochrome c release. We showed that MPsShh+ treatment significantly
prevented HUVECs apoptosis evoked by ActD. Also, caspases inhibitor z-vad.fmk (50
μM ) reduced cell death either in presence or in absence of MPsShh+, indicating the
implication of caspases in ActD-induced apoptosis. To investigate the implication of
Shh pathway in this effect, its agonist SAG and its antagonist CUR61414 were tested.
SAG reduced apoptosis in a dose-dependent manner; by itself, CUR61414 had no
effect on its own but abolished the antiapoptotic effect of MPsShh, revealing a
contribution of Shh pathway. In contrast, MPsShh+ were still able to reduce
apoptosis in the presence of NO synthase inhibitor, L-NA (100 μM ), or when the PI3-
kinase and ERK were inhibited with LY294002 (10 μM ) and U0126 (10 μM )
respectively, showing that these pathways were not associated with protection
against apoptosis. Besides, we explored changes in ROS production at different
times, by electronic paramagnetic resonance. ROS levels were increased in ActD-
treated cells at 2 h and 10 h. This elevation was prevented by MPsShh+ only at 2 h.
When sources of ROS, xanthine oxidase, NAD(P)H oxidase and respiratory chain
complex I, were inhibited using allopurinol (50 μM ), apocynin (100 μM ) and
rotenone (5 μM), respectively, we found that only rotenone reduced ActD-induced
apoptosis. Also, the superoxide dismutase (SOD) mimetic, MnTMPyP (100 μM ),
reduced ActD-evoked cell death and the protective effect of MPsShh+. These results
indicate that, under these experimental conditions, MPsShh+ may act in the early
phase of apoptosis at mitochondrial level and behave as a SOD mimetic. These
findings provide additional mechanisms by which MPsShh+ exert their
vasculoprotective effects, preserving integrity of endothelial monolayer. Supported
by ANR-07-PHYSIO-010-01.
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